1 Unprofitable Stock to Consider Right Now and 2 We Turn DownUnprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst QuestionsMyriad Genetics began 2026 with results that fell short of Wall Street’s expectations, as the company posted modest year-over-year sales growth but missed on...
3 of Wall Street’s Favorite Stocks with Open QuestionsThe stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure MarginsGenetic testing company Myriad Genetics (
NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.3% year on year to $200.4 millio...
Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%Genetic testing company Myriad Genetics (
NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.3% year on year to $200.4 millio...
Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To ExpectGenetic testing company Myriad Genetics (
NASDAQ:MYGN) will be reporting earnings this Tuesday after market close. Here’s what you need to know. Myriad Geneti...
3 Small-Cap Stocks We Think Twice AboutSmall-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
1 Cash-Burning Stock to Target This Week and 2 We QuestionRapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics StocksQuarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
3 Healthcare Stocks with Open QuestionsFrom novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To KnowWhat Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and TeladocCheck out the companies making headlines yesterday: nLIGHT (
NASDAQ:LASR): Laser company nLIGHT (
NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted...
3 Reasons to Sell MYGN and 1 Stock to Buy InsteadShareholders of Myriad Genetics would probably like to forget the past six months even happened. The stock dropped 31.8% and now trades at $5.24. This may ha...
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To KnowWhat Happened? Shares of genetic testing company Myriad Genetics (
NASDAQ:MYGN) jumped 6.9% in the afternoon session after its President and CEO, Samraat Raha...
3 Stocks Under $10 We Keep Off Our RadarInvestors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many ...
2 Unprofitable Stocks on Our Buy List and 1 We Brush OffUnprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Myriad Genetics (MYGN) Stock Trades Up, Here Is WhyWhat Happened? Shares of genetic testing company Myriad Genetics (
NASDAQ:MYGN) jumped 5.9% in the afternoon session after the company announced the launch of...
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To KnowA number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key measure of inflation at the wholesale level, increased by 0.5% in January, significantly higher than the 0.3% anticipated by economists. More concerning was the core PPI, which excludes volatile food and energy prices, as it surged by 0.8%, far exceeding the expected 0.3% rise. This data suggests that inflation may be more entrenched than previously thought, potentially impacting future interest rate decisions. In response to the news, major market indices, including the S&P 500, Dow Jones, and Nasdaq, all traded sharply lower as investors reassessed the economic outlook.
Why Myriad Genetics (MYGN) Stock Is Trading Up TodayShares of genetic testing company Myriad Genetics (
NASDAQ:MYGN)
jumped 4.9% in the morning session after the company reported better-than-expected fourth-quarter 2025 earnings that surpassed analyst forecasts for both revenue and profit.
Myriad Genetics’s (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22%Genetic testing company Myriad Genetics (
NASDAQ:MYGN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full year’s revenue to be around $870 million, close to analysts’ estimates. Its non-GAAP profit of $0.04 per share was significantly above analysts’ consensus estimates.
